University of British Columbia
Dissecting the cell of origin and progression events of DICER1 syndrome-associated sarcoma
Abstract
dc:descriptionDICER1 syndrome is a rare genetic disorder driven by germline DICER1 inactivating pathogenic variants that predispose pediatric and young adult patients to cancers at various sites. The second, missense mutation in RNase IIIb domain on the alternate allele leads to partial inactivation, compromising its capability in the processing of its targets, e.g., microRNAs. Malignant tumours at various sites are mostly sarcomas that are histologically and molecularly similar, suggesting a shared cellular origin and oncogenic mechanisms. Recently, the Huntsman laboratory has developed a lineage-traceable genetically engineered mouse model that allows for controlled activation of Dicer1 biallelic mutations in Hic1⁺ mesenchymal stromal cells, resulting in the development of renal tumours resembling the human DICER1 sarcoma histologically and molecularly. To uncover the cellular origin and developmental hierarchy, I utilized this model and relevant control lines to dissect the tumour development trajectory. Single-cell transcriptomics analysis of 5 primary tumours revealed a Hic1⁺Pdgfra⁺Mfap4⁺ fibroblastic progenitor population that was identified as universal fibroblasts at normal kidneys. These cells have the capacity to undergo rhabdomyoblastic differentiation or transition into proliferative sarcomatous cells. To facilitate mechanistic characterization, we derived 5 cell lines from primary murine tumours, and 4 of which harboured de novo Trp53 and Kras mutations. Trp53-mutant cells were more resistant to chemotherapies such as vincristine and doxorubicin currently used to treat pleuropulmonary blastoma, the most common DICER1 sarcoma. To identify tumour progression events and associated targetable, perturbed pathways, I performed a curated CRISPR/Cas9 knockout screen for 484 tumour suppressor genes in the cell line harbouring no obvious secondary mutations. Tumour suppressors such as Trp53, Pten, Cdkn2b (p15), Nf1, and Sav1 were identified as candidates. The relevance to disease progression was supported by higher frequency of their protein losses in more advanced DICER1 sarcomas. Loss of Sav1, an effector of the Hippo pathway, is partially correlated with YAP nuclear translocation that promotes proliferation. Activation of MAPK/ERK and inactivation of the Hippo pathway were observed in more advanced DICER1 sarcomas, suggesting synergistic treatment would be beneficial. Overall, our work uncovers a fibroblastic origin for DICER1 sarcoma and identifies critical progression events, providing rationale for a more targeted therapeutic approach.
Degree
thesis:*- Name thesis:degree_name
- Doctor of Medicine / Doctor of Philosophy - MD/PhD
- Level thesis:degree_level
- doctoral
- Discipline thesis:degree_discipline
- Pathology and Laboratory Medicine
- Grantor dc:publisher
- University of British Columbia
- Year dc:date
- 2025
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Zhang, Yu Han (Joyce)
- Contributors dc:contributor
-
- Huntsman, David G.
- Wang, Yemin
Rights
dc:rights- Statement dc:rights
-
- Attribution-NonCommercial-NoDerivatives 4.0 International
- Language dc:language
- eng
Identifiers
dc:identifier.*- Handle dc:identifier
- http://hdl.handle.net/2429/91375